Shares in gastrointestinal biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are plunging by 30% this week, following the announcement of an equity offering to raise money. …
Two healthcare companies with recently approved and much-hyped products- but which one makes a compelling investing opportunity right now? Synergy Pharmaceuticals Inc (NASDAQ:SGYP) specializes …
Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.
By Bret Jensen Small biotech stocks especially ‘Tier 3‘ concerns like Omeros and Flexion Therapeutics have been taking it on the shin for most …
H.C.
Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Investors to get a better viewpoint of Trulance during today’s call, says analyst.
